Olmesartan-based therapies

Sierra, Alejandro de la; Volpe, Massimo

doi:10.1097/hjh.0b013e32835d2b05

Cited by 10 publications

(5 citation statements)

References 43 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…1,21 It is available as a dual combination product with hydrochlorothiazide or amlodipine and as a triple combination preparation with both of these agents. 21 No clinical trials demonstrating reductions in cardiovascular morbidity and mortality outcomes have been published. 22 The ongoing 1147 patient Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients with Stable Heart Failure Using Olmesartan (SUPPORT) trial is evaluating the efficacy of olmesartan compared with non-ARB antihypertensives in reducing a composite of all-cause mortality, nonfatal acute myocardial infarction, nonfatal stroke, and hospital admissions for heart failure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

Olmesartan has been linked with increased risk of cardiovascular mortality and sprue-like enteropathy. We compared outcomes between olmesartan and other angiotensin receptor blockers in a large clinical registry of patients with diabetes mellitus. A retrospective cohort analysis using nationwide US-integrated insurance and laboratory claims was performed in 45 185 incident diabetic angiotensin receptor blocker users, including 10 370 (23%) olmesartan users. Hazard ratios were computed using time-dependant Cox models adjusted for sociodemographic characteristics, comorbidities, laboratory data, drug use, healthcare utilization, and the propensity to receive olmesartan. Blood pressure data were unavailable. Subjects were followed up for 116 721 patient-years. The primary end point was all-cause hospitalization or all-cause mortality and occurred in 10 915 (24%) patients. Average age was 54.3±9.6 years, 52% were men, 17% had cardiovascular disease, and 10% chronic kidney disease. Compared with other angiotensin receptor blockers, the adjusted hazard for olmesartan was 0.99 (95% confidence interval, 0.94–1.05) for all-cause hospitalization and mortality; 0.90 (0.62–1.30) for all-cause mortality; 0.99 (0.94–1.05) for all-cause hospital admission; 0.88 (0.78–1.00) for cardiovascular disease–related admission, and 1.09 (0.98–1.20) for gastrointestinal disease–related hospitalization in the overall cohort. Olmesartan use was associated with an adjusted hazard for the primary outcome of 1.11 (0.99–1.24) in subjects with history of cardiovascular disease and 1.21 (1.04–1.41) in subjects with chronic kidney disease. In conclusion, there is no robust signal for harm with olmesartan use. Risk may be increased in kidney disease; thus, given the widespread availability of alternate agents, olmesartan should be used with caution in this subgroup pending further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Indeed, in a very large randomized controlled trial (ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) performed on about 30,000 patients, ACEIs and ARBs did not show any significant difference in myocardial infarction or any of the CV efficacy outcomes [30]. In addition to this, several meta-analyses have provided evidence that ARBs are as protective as ACEIs [31–33]. In a real-world practice study, however, ARBs reduced by 10% the incidence of CV mortality, non-fatal myocardial infarction, non-fatal stroke or hospitalization for CV disease at 4 years, providing superior protection against CV events than ACEIs in high-risk patients [34].…”

Section: Are Angiotensin Converting Enzyme Inhibitors and Angiotensinmentioning

confidence: 99%

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan

Omboni

Volpe

2018

Adv Ther

Self Cite

View full text Add to dashboard Cite

Blood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin–angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10% the incidence of CV mortality, non-fatal myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite similar antihypertensive properties and a favourable safety profile for both ACEIs and ARBs, evidence indicates that patients treated with ARBs have lower rates of withdrawal for adverse events and greater persistence to therapy than those treated with ACEIs. Among ARBs, olmesartan is one of the latest generation compounds introduced in clinical practice for treating hypertension: head-to-head comparative trials suggest that the efficacy of olmesartan is superior to that of commonly prescribed ACEIs (ramipril and perindopril). The drug, administered as a monotherapy or in combination with a dihydropyridine calcium channel blocker or a thiazide diuretic, has proved to be effective in maintaining blood pressure stability over 24 h, with a favourable safety profile and low discontinuation rates. These properties are pivotal for considering olmesartan as a useful antihypertensive agent especially for high-risk patients (e.g. elderly, diabetics, patients with metabolic syndrome).Funding: Article preparation and open access fee were funded by Menarini International Operations Luxembourg S.A. (M.I.O.L.)

show abstract

“…Several clinical studies showed that co-therapy of Olmesartan versus Olmesartan monotherapy effectively decreases blood pressure and reduces blood glucose levels, insulin, total cholesterol, triglyceride, and leptin [6]. OLM has been the subject of numerous trials focused on organ protection, revealing favourable outcomes in various disease markers such as microinflammation reduction, regression of plaque volume and vascular hypertrophy, and prevention of microalbuminuria [7]. It is reported that OLM treatment for eight weeks results in a higher decrease in cuff DBP (diastolic blood pressure) than subsequent treatments with losartan, valsartan, or irbesartan.…”

Section: Introductionmentioning

confidence: 99%

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

Rind,

Mahmood,

Siddiqui

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug’s established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan’s versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug’s favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts.

show abstract

Olmesartan-based therapies

Cited by 10 publications

References 43 publications

Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus

Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

Contact Info

Product

Resources

About